Pulmonx在10月29日报告2025年Q3结果,同时提供电话会议和网播。 Pulmonx to report Q3 2025 results on Oct. 29, with a conference call and webcast.

Pulmonx公司将在2025年10月29日市场关闭后发布其2025年第三季度的财务结果,并在下午1时30分主办一次电话会议,讨论这些结果。 Pulmonx Corp. will release its third-quarter 2025 financial results after market close on October 29, 2025, and host a conference call at 1:30 p.m. PT to discuss them. 该活动将通过网播进行,并存档在公司投资者网站上。 The event will be available via webcast and archived on the company’s investor website. Pulmonx开发了对严重肺气肿和青蒿素综合症的最低侵入性治疗方法,包括经林业发展局批准的Zephyr Endobronchial Valve,该治疗方法在超过25个国家使用,并被公认为护理标准。 Pulmonx develops minimally invasive treatments for severe emphysema and COPD, including the FDA-approved Zephyr Endobronchial Valve, which is used in over 25 countries and recognized as a standard of care. 公司还提供相关的诊断和分析工具。 The company also offers related diagnostic and analysis tools.